-+ 0.00%
-+ 0.00%
-+ 0.00%

French pharmaceutical group Sanofi has agreed to acquire American biopharmaceutical company Blueprint Medicines Corporation. Under the terms of the acquisition, Sanofi will pay $129 per share in cash, with a total transaction price of approximately $9.1 billion. Sanofi CEO Paul Hudson said that the acquisition represents a strategic step in the company's rare disease and immunology product portfolio. In addition to strengthening the product line, it also accelerates the company's transformation into a world-leading immunology company.

Zhitongcaijing·06/02/2025 12:09:21
Listen to the news
French pharmaceutical group Sanofi has agreed to acquire American biopharmaceutical company Blueprint Medicines Corporation. Under the terms of the acquisition, Sanofi will pay $129 per share in cash, with a total transaction price of approximately $9.1 billion. Sanofi CEO Paul Hudson said that the acquisition represents a strategic step in the company's rare disease and immunology product portfolio. In addition to strengthening the product line, it also accelerates the company's transformation into a world-leading immunology company.